Literature DB >> 21092432

Management of primary rectal cancer by surgeons in Atlantic Canada: results of a regional survey.

Teong Kuan Chuah1, Tracy Lee, Debrah Wirtzfeld, William Pollett.   

Abstract

BACKGROUND: We sought to determine the current practice patterns of general surgeons in Atlantic Canada in the management of primary rectal cancer in relation to surgeon-specific variables.
METHODS: We sent mail-out surveys to all practising general surgeons (n = 183) in Atlantic Canada to determine screening preferences, preoperative assessment, the use of neoadjuvant and adjuvant therapy, surgical therapy for rectal cancer and surgeon demographics. We analyzed the responses using χ(2) tests.
RESULTS: The response rate was 98 (54%) after 2 mail-outs; there were 82 (49%) eligible responses. Surgeons in practice for 21 years or more were more likely than those with fewer than 21 years of practice to order preoperative ultrasonography of the liver and were less likely to order preoperative computed tomography. Endorectal ultrasonography was ordered routinely by 23% of surgeons, whereas 71% of surgeons would order it if time and resources were available. Surgeons who were not certified by the Royal College of Physicians and Surgeons of Canada were significantly more likely than those who were certified to use neoadjuvant therapy in all patients with rectal cancer (43% v. 12%; p = 0.031). Surgeons who performed more than 10 rectal cancer surgeries per year were significantly more likely than those who performed 10 or fewer surgeries per year to use neoadjuvant treatment for T3 tumours (94% v. 61%; p = 0.007). Surgeons with medical or radiation oncology services in their communities were significantly more likely than those without such services to recommend neoadjuvant treatment in T3 rectal tumours and rectal tumours with pathologic lymph nodes.
CONCLUSION: We found significant variation in the management of rectal cancer depending on surgeon-specific variables. The implications of these differences on the outcomes of patients with rectal cancer are unknown.

Entities:  

Mesh:

Year:  2010        PMID: 21092432      PMCID: PMC2993032     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  15 in total

1.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

Authors:  Joakim Folkesson; Helgi Birgisson; Lars Pahlman; Bjorn Cedermark; Bengt Glimelius; Ulf Gunnarsson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Evaluating learning and knowledge retention after a continuing medical education course on total mesorectal excision for surgeons.

Authors:  Rona E Cheifetz; P Terry Phang
Journal:  Am J Surg       Date:  2006-05       Impact factor: 2.565

3.  Effect of the introduction of total mesorectal excision for the treatment of rectal cancer.

Authors:  E Carlsen; E Schlichting; I Guldvog; E Johnson; R J Heald
Journal:  Br J Surg       Date:  1998-04       Impact factor: 6.939

4.  Surgeon-related factors and outcome in rectal cancer.

Authors:  G A Porter; C L Soskolne; W W Yakimets; S C Newman
Journal:  Ann Surg       Date:  1998-02       Impact factor: 12.969

5.  Preoperative radiotherapy improves outcome in recurrent rectal cancer.

Authors:  Maarten Vermaas; Floris T J Ferenschild; Joost J M E Nuyttens; Andreas W K S Marinelli; Theo Wiggers; Joost R M M van der Sijp; Cornelis Verhoef; Wilfried J Graveland; Alexander M M Eggermont; Johannes H W de Wilt
Journal:  Dis Colon Rectum       Date:  2005-05       Impact factor: 4.585

6.  Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival.

Authors:  C S McArdle; D Hole
Journal:  BMJ       Date:  1991-06-22

7.  Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients.

Authors:  K Havenga; W E Enker; J Norstein; Y Moriya; R J Heald; H C van Houwelingen; C J van de Velde
Journal:  Eur J Surg Oncol       Date:  1999-08       Impact factor: 4.424

8.  The investigation of primary rectal cancer by surgeons: current pattern of practice.

Authors:  Todd P W McMullen; Alexandra M Easson; Zane Cohen; Carol J Swallow
Journal:  Can J Surg       Date:  2005-02       Impact factor: 2.089

9.  Understanding variation in the management of rectal cancer: the potential of a surgeon-initiated database.

Authors:  Neil Hyman; Christopher Healey; Turner Osler; Peter Cataldo
Journal:  Am J Surg       Date:  2007-10       Impact factor: 2.565

Review 10.  Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma.

Authors:  R K S Wong; V Tandan; S De Silva; A Figueredo
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
View more
  5 in total

1.  Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium.

Authors:  Mary E Charlton; Chi Lin; Dingfeng Jiang; Karyn B Stitzenberg; Thorvardur R Halfdanarson; Jane F Pendergast; Elizabeth A Chrischilles; Robert B Wallace
Journal:  Am J Clin Oncol       Date:  2013-12       Impact factor: 2.339

2.  Self-reported practice patterns and knowledge of rectal cancer care among Canadian general surgeons.

Authors:  Devon P Richardson; Geoff A Porter; Paul M Johnson
Journal:  Can J Surg       Date:  2014-12       Impact factor: 2.089

3.  Management of rectal cancer in Canada: an evidence-based comparison of clinical practice guidelines

Authors:  Zuhaib M. Mir; David Yu; Shaila J. Merchant; Christopher M. Booth; Sunil V. Patel
Journal:  Can J Surg       Date:  2020-01-22       Impact factor: 2.089

Review 4.  Barriers to accessing radiation therapy in Canada: a systematic review.

Authors:  Caitlin Gillan; Kaleigh Briggs; Alejandro Goytisolo Pazos; Melanie Maurus; Nicole Harnett; Pamela Catton; David Wiljer
Journal:  Radiat Oncol       Date:  2012-10-12       Impact factor: 3.481

5.  Physician self-reported treatment of brain metastases according to patients' clinical and demographic factors and physician practice setting.

Authors:  Marie-Adele S Kress; Naren Ramakrishna; Solomon B Makgoeng; Keith R Unger; Arnold L Potosky
Journal:  Radiat Oncol       Date:  2012-11-08       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.